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SUMMARY
The effect of prior infection with cytomegalovirus (CMV) on progression of HIV
disease in a cohort of 111 men with haemophilia was studied after 13 years follow-
up. The relative hazards associated with CMV positivity on progression to AIDS,
death and a CD4 count of 0-05 x 10
9/l were 2-28, 2-42 and 2-34, respectively. CMV
seropositive patients were significantly older than the seronegative and this was
controlled for by using a Cox proportional hazards model. The relative hazards for
the three endpoints decreased to 1-89, 1-82 and 1-93 respectively and were
marginally non-significant (P = 0-05, 0-08 and 0-08 for the three endpoints
respectively). We conclude that this cohort continues to show evidence of a 'co-
factor ' effect associated with prior infection with CMV which is confounded by age
but not completely explained by age differences. The potential biological
significance of these results is discussed in the context of recent controlled clinical
trials which show a survival benefit from long-term high-dose acyclovir, a drug
with activity in vivo against CMV and other herpesviruses.
INTRODUCTION
Although the human immunodeficiency virus (HIV) is the known cause of the
acquired immune deficiency syndrome (AIDS), the incubation period from
infection with HIV to the development of AIDS is long and variable [1-4]. This
wide variation in the incubation period is far greater than that found for most
other acute viral diseases, suggesting that other factors may contribute to disease
progression. Among these, infectious agents, termed co-factors, could interact
with HIV and increase its pathogenicity.
Different viruses could interact with HIV by a variety of mechanisms [5]. For
example, some viruses, including herpes simplex virus (HSV), cytomegalovirus
(CMV), hepatitis B virus and Epstein-Barr virus have all been shown to362 C. A. SABIN AND OTHERS
transactivate HIV in vitro [6—9]. However, there are only a few studies which
assess the relative importance of these viral co-factors in vivo. It is well
documented that older individuals experience more rapid progression of HIV
disease than younger individuals, perhaps due to a more rapidly declining immune
system in older individuals [10-12]. As the prevalence of antibodies to HSV and
CMV increases with age [13], any assessment of the potential effect of these viruses
on progression of HIV disease must take account of the possible confounding effect
of age.
We have chosen to study whether CMV could act as a co-factor for HIV disease
in a cohort of men with haemophilia in whom the prevalence of CMV infection is
60 %, similar to that seen in young blood donors and attenders at antenatal clinics
[14]. We have previously reported that in this cohort prior CMV infection is
associated with more rapid progression to AIDS [15] but this has not been
confirmed by others [16-19]. Here we extend follow-up to 13 years to assess
whether this association remains after adjustment for age differences. Fur-
thermore, sufficient follow-up is now available on the patients to analyse both
survival and immune depletion as endpoints.
MATERIALS AND METHODS
Patients and their clinical management
A total of 111 men with haemophilia registered at the Royal Free Hospital
Haemophilia Centre, London, became infected with HIV between 1979 and 1985
following treatment with unsterilized blood clotting factor concentrates [20, 21].
All patients are seen at the Centre approximately every 3-6 months when they
undergo a clinical and laboratory review. Serum samples are regularly taken and
stored at —20 °C. It has been possible retrospectively to test these serum samples
for HIV seropositivity and hence dates of seroconversion have been estimated for
all patients [20].
Zidovudine has been available for individuals with AIDS and AIDS-related
complex (ARC) since 1987, and from October 1988 it has been available as part of
the MRC/Agence Nationale de Recherches sur le SIDA (ANRS) Concorde trial of
early versus deferred zidovudine. Secondary prophylaxis for Pneumocystis carinii
pneumonia (PCP) with pentamidine or co-trimoxazole has been available since
March 1988, and primary prophylaxis since February 1989. Secondary prophylaxis
for candidiasis with fluconazole has been available since March 1988 and primary
prophylaxis since April 1990. All patients are advised to start zidovudine and
primary prophylaxis once their CD4 count is < 0-2 x 10
9/l. Patients developing
either PCP or candidiasis are offered secondary prophylaxis regardless of their
CD4 count. To date 51 patients have received zidovudine, 35 PCP prophylaxis (26
primary, 9 secondary) and 39 prophylaxis for candidiasis (13 primary, 26
secondary). Currently, whilst acyclovir may be given to patients experiencing
herpes zoster repeatedly, it is not routinely prescribed for patients in the cohort.
Laboratory methods
Between 1982 and 1986 absolute CD4 counts were calculated from the
lymphocyte count and CD4 percent values [20]. A whole blood lysis method hasEffect of CMV status on HIV progression 363
been used since 1986, and the percentage of CD4 lymphocytes analysed by flow
cytometry, using a FACScan (Becton Dickinson, Crawley, UK) [22]. A monoclonal
CD4 antibody (RFT4) to the p55 CD4 antigen was used with a monoclonal CD3
antibody (UCHT1) as described previously [22]. More recently absolute CD4
counts have been directly obtained on an ORTHO Cytoron-Absolute (ORTHO
Diagnostics, High Wycombe, UK). Quality control of flow cytometry was
monitored as part of the UK National External Quality Assurance Scheme. We
have compared CD4 counts in these patients from before and after the change in
methods in 1986 and have seen no consistent difference. Antibodies to CMV were
measured on early stored serum samples by radioimmunoassay as described
elsewhere [23].
Statistical methods
Comparisons of patients with and without antibody to CMV were done using
standard non-parametric methods (Mann-Whitney U test [24]). Analyses which
assessed the effect of CMV on HIV disease progression were performed using
standard survival methods. Plots of survival from seroconversion to endpoints of
AIDS and death were estimated using Kaplan—Meier methods [25] and the
univariate effect of CMV status on these were tested for significance using the log-
rank test. Cox proportional hazards models [26] were used to assess the
independent effect of CMV status on disease progression after adjusting for the
patient's age and CD4 count in multivariate models using the procedure 'PROC
PHREG' in the Statistical Analysis System (SAS) package [27]. For this analysis,
progression to an endpoint of a CD4 count of O05 x 10
9/l was also used. The low
CD4 count of O05 x 10
9/l was chosen as an endpoint due to the rapidly increasing
risk of death once the CD4 count has fallen to this level [28]. The approximate date
on which the CD4 count fell to O05 x 10
9/l was estimated by linear interpolation.
When studying progression to AIDS or a low CD4 count, patient follow-up was
right-censored at death or at the cut-off date for the analysis (31 December 1992),
if the patient had not developed AIDS or reached a low CD4 count by that time.
When studying progression to death, patient follow-up was right-censored at
December 1992 if still alive on that date. CMV status and age at seroconversion
were considered to remain fixed throughout follow-up, and the patient's CD4
count was modelled as a time-dependent covariate. In order to assess the validity
of the proportional hazards assumption, an interaction term between the
logarithm of time and CMV status was added to the model and tested for
significance.
In order to estimate the potential effect of CMV positivity on death at certain
CD4 levels, the dates on which the CD4 count was estimated to fall below certain
levels (0-2, 0-3, 0-4, 0-5, 0-6 x 10
9/l) were calculated using linear interpolation.
Survival methods were used to assess the prognosis associated with CMV
seropositivity, after adjustment for patient age at each CD4 baseline date.
In the UK, prophylaxis for PCP and candidiasis and antiretroviral therapy
(zidovudine) for patients without AIDS became available from 1987 onwards. The
direct modelling in this cohort of treatment effects is limited as few data are
available on individual treatment usage in the cohort. Further, most treatment is
instigated once the CD4 count falls below 0
-2 x 10
9/l, resulting in treatment effectsMedian
CMV-positive
59
May 1982
Range Oct 1979-Mar 1985
Median
Range
* P-value =
t P-value =
25-6
4-0-77-8
30(50-8%)
30(50-8%)
= 0-77.
= 003.
CMV-negative
50
April 1982
Nov 1979-Jul 1985
18-7
2-1-73-0
14 (28-0%)
12 (24-0%)
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Table 1. Comparison of CMV-positive and CMV-negative patients in the cohort
Patient characteristics
Number of patients
Date of seroconversion*
Age at serocon version (years) f
Number developing AIDS
Number of deaths
which are confounded with those of the CD4 count. Consequently, in order to
assess whether these results were independent of the treatment, all analyses were
repeated with the inclusion of an additional covariate to represent simply the
availability of pre-AIDS prophylaxis and antiretroviral therapies. This was
included in the model as a time-dependent covariate taking the value of zero
before November 1987 and one after. This then allows for the fact that patients
who have survived at least to November 1987 have the added survival advantage
of any therapy available to them, whether or not they actually receive it.
RESULTS
Antibodies to CMV were measured on early blood samples from patients in the
cohort. 59/109 (54%) were found to have antibody to CMV. CMV status is
unknown for two patients. A comparison of the patients known to be seropositive
and seronegative for CMV is shown in Table 1. CMV positive patients were older
at seroconversion to HIV, but in general they did not seroconvert any earlier or
later than those who were CMV negative.
By the end of 1992, a total of 44 of the patients had developed AIDS and 42 had
died, with Kaplan-Meier progression rates of 47-1 and 48-3% by 13 years,
respectively. CD4 counts had fallen below 0-05 x 10
9/l on at least one occasion in
35 patients, a progression rate of 43-3% by 13 years after seroconversion.
Unadjusted for age, CMV status was significantly associated with a faster
progression to AIDS (P = 0-009, log-rank test) and to death (P = 0-008, log-rank
test). Progression rates to AIDS and death, stratified by CMV status are shown in
Figs 1 and 2. The effect of CMV status on progression to AIDS and death remains
apparent, although reduced slightly, in both older and younger individuals.
Cox proportional hazards models were used to quantitate the effects of CMV
seropositivity on the hazards of developing AIDS, of dying or of reaching a low
CD4 count, after adjusting for age at HIV seroconversion (Table 2). Using this
approach, before adjusting for age, patients known to be CMV positive were over
twice as likely to develop AIDS, die or reach a low CD4 count as those known to
be CMV negative. After adjusting for the patient's age at seroconversion, the effect
of CMV positivity on progression to all three end points decreased slightly and
became marginally non-significant (P = 0-05, 0-08 and 0*08 for progression to
AIDS, death and a CD4 count < 0-05 x 10
9/l respectively). In order to assess
whether the effect of CMV status acts through the CD4 count, the relative hazardsEffect of CMV status on HIV progression 365
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Fig. 1. Kaplan-Meier curves showing progression from HIV seroconversion to the
development of AIDS, stratified by CMV status at seroconversion for (i) all patients,
(ii) patients sj 35 years at seroconversion, and (iii) patients > 35 years at
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Fig. 2. Kaplan-Meier curves showing progression from HIV seroconversion to death,
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Table 2. Relative hazards (and 95% confidence intervals) of progression to AIDS,
death or a CD4 count of 0-05 x 10
9/l associated with CMV positivity unadjusted for
other factors, and with CMV positivity after adjustment for patients' age at
seroconversion and most recent CD4 count
Unadjusted
Adjusted for age
Adjusted for age and CD4 count*
AIDS
2-28
(1-20-4-31)
1-89
(0-99-3-60)
2-17
(113-416)
Progression to
A
Death
2-42
(1-24-4-73)
1-82
(0-93-3-58)
1-73
(0-88-3-39)
CD4 0-05 x 10
9/]
2-34
(1-14-4-79)
1-93
(0-93-4-01)
—
—
* Progression to CD4 count of 005 x 10
9/l is not adjusted for most recent CD4 count.
Table 3. Relative hazards (and 95% confidence intervals) of death associated with
CMV status. Baseline dates are defined as the date on which the CD4 count first fell
below certain levels. Relative hazards for CMV status are adjusted for age at
baseline
Baseline
CD4 count
( x 10
9/l)
0-2
0-3
0-4
0-5
0-6
No. of
patients
60
66
69
59
54
No. of
events
30
26
23
21
19
Relative hazard
1-79
2-83
2-40
2-71
1-74
95% CI
0-80-404
112-714
0-92-6-27
0-95-7-77
0-61-4-92
of developing AIDS and dying associated with CMV status are also shown in Table
2 after adjustment for the patients' most recent CD4 count, updated as a time-
dependent covariate. After this additional adjustment the effect of CMV on
survival was further reduced, whilst the effect of CMV on progression to AIDS
returned towards its original value and attained statistical significance. Because
of its obvious relationship with the most recent CD4 count, the relative hazard
associated with CMV positivity on progression to a CD4 count of 0-05 x 10
9/l was
not adjusted for the patients' CD4 counts during follow up.
The addition of an interaction term between CMV status and log(time) to the
model did not significantly improve the fit of the model (P = 0-71), suggesting that
the proportional hazards assumption was reasonable.
Examination of the Kaplan-Meier plots suggested that the CMV effect may be
smaller in younger patients than in older patients. However, the addition of an
interaction term between CMV status and age was not significant for any of the
three endpoints (P = 0-85, 0-78 and 0-88 for progression to AIDS, death and a CD4
count of 0-05 x 10
9/l respectively).
In order to assess whether the hazard of death associated with CMV
seropositivity was dependent on the CD4 count of the patient, the proportional
hazards model was fitted with baseline dates defined as the first time a patients
CD4 count fell to a certain level (0-2, 0-3, 0-4, 0-5, 0-6 x 10
9/l). Results from this368 C. A. SABIN AND OTHERS
analysis are shown in Table 3 and indicate that the size of effect of CMV status
remains reasonably constant, after adjustment for age at CD4 baseline at all CD4
baselines.
The analyses were repeated with the addition of a term representing the
availability of pre-AIDS prophylaxis and antiretroviral therapies. With the
inclusion of this term the results were essentially unchanged.
DISCUSSION
The results presented here show that there is an association between CMV
seropositivity and HIV disease progression measured by the time to AIDS, and
also time to a low CD4 count and time to death. Whilst some of these effects may
be explained by differences in age at seroconversion in the two groups, there
remains a residual effect of CMV status on progression to AIDS which is
unexplained by adjustment for this factor. We will discuss our findings and those
of others for each of the three endpoints assessed.
Time to AIDS
For the time to AIDS we find an effect of CMV status (relative hazard 2-28)
which is somewhat lower (relative hazard 3-2) than we reported in 1989 [15]. After
controlling for age the relative hazard has also declined from 2-5 to 1-9. The results
depicted in Figs 1 and 2 show that CMV seropositive patients progress to AIDS
more rapidly than seronegative patients, even when considering younger and older
individuals separately. After adjustment for patient age in the Cox proportional
hazard model, the relative hazard fails to reach the conventional 5% level of
significance (Table 2). However, the fact that the lower limit of the confidence
interval is only marginally below 1 suggests that strict adherence to this
convention is not sensible; a slight change in either the length of follow-up or an
extra AIDS case could esily lead to a relative hazard which was the same but
statistically significant. We conclude that prior CMV infection approximately
doubles the risk of progression to AIDS. Comparisons of the Kaplan-Meier plots
within the two age groups with those generated from all patients show that age
differences do not completely explain the CMV effect. Unfortunately we do not
have information on when patients seroconverted to CMV. There is a suggestion
that the CMV effect is smaller in younger individuals than in older individuals. If
any effect of CMV status on progression of HIV disease exists, then those who
have been infected with CMV for longest and who are also likely to be those who
were older at HIV seroconversion, may experience the greatest effect of CMV on
the progression of their disease. However, there is no evidence of an interaction
between age and CMV status. This suggests that this is unlikely to be the case so
that the differences which are apparent from the Kaplan-Meier plots are more
likely to be the result of random variation due to the small numbers of individuals
who are younger and who have antibody to CMV. Two of the AIDS-defining
conditions, CMV retinitis and other CMV disease, are CMV-related [29] and so this
might be one possible explanation for our findings. However, in our cohort only
one patient developed either of these two conditions as his initial AIDS-defining
condition, showing that this relationship cannot expain our results.Effect of CMV status on HIV progression 369
A number of other studies have reported findings on the potential effect of CMV
positivity on HIV disease progression. Three studies [16-18] found no statistically
significant effect of CMV on progression to symptomatic HIV infection or AIDS.
However, these studies had flaws either in design or conduct [30]. Results from a
recent study from the United States of men with haemophilia with known dates
of HIV seroconversion [19] did not find a significantly raised risk of AIDS
associated with CMV seropositivity after adjustment for age, and offered the
strongest evidence against the hypothesis that CMV status is associated with rapid
disease progression. The patients included in that study were of a similar age range
to those in our study and the proportion who were CMV positive was also similar.
Serum samples were tested for CMV antibody under code in London using the
same radioimmunoassay, thus removing the effect of laboratory differences.
Because both studies are carried out in haemophilic patients, the effects of other
possible co-factors (e.g. gender, HIV exposure category, intravenous drug use,
etc.) on progression rates between the two studies are unlikely to explain these
differences. However, it may be possible that differences in covariates other than
those currently known to be associated with progression of HIV disease could
explain the contrasting results, and we are continuing to collaborate with the USA
investigators to study this with the aim of identifying other previously
unrecognized factors which may explain the differences. These may include
differences in patient selection methods or in the background prevalence rates of
antibodies to other viruses in the patient populations.
Survival
Sufficient follow-up has now occurred in our cohort to allow an analysis of
survival which shows a raised risk of death associated with CMV seropositivity.
The association of CMV status with death is not attributable to clinically
recognized CMV disease. Thus there is no evidence that CMV is causing
opportunistic disease and we have argued elsewhere that this supports the concept
of CMV as a ' co-factor', increasing the burden of disease without declaring itself
clinically [5]. This concept is supported by autopsy findings that CMV is present
in at least one tissue in 66% of AIDS patients [31].
It is interesting to speculate on the clinical effects of anti-CMV therapy
administered to AIDS patients. Recently, two controlled trials used acyclovir in
homosexual men with advanced HIV disease [32, 33]. In both trials an
approximately 40% reduction in the number of deaths was seen in patients
receiving acyclovir compared to those in the control group. As acyclovir is known
to inhibit the DNA polymerase enzyme of several herpesviruses, such a virus could
be involved in the pathogenesis of death in AIDS patients. CMV is a strong
candidate in this setting because CMV has been found by cell culture in the
majority of AIDS patients coming to autopsy [31] and because controlled trials in
transplant patients have shown that high-dose acyclovir can decrease CMV
replication and disease [34-36]. All patients in these trials were CMV positive and
had low CD4 counts. Results from Table 3 suggest that at low CD4 counts a
relative hazard value < 2 associated with death is reasonable and consistent with
the approximate halving of the death rate in these two trials, which again suggests
that the inhibition of CMV replication is a plausible reason for the reduced370 C. A. SABIN AND OTHERS
mortality seen. Further studies of quantitative CMV virology during such trials
will be required to determine if suppression of CMV, and/or other herpesviruses,
correlates with improved survival. This work is in progress under the auspices of
the AIDS Clinical Trials Group.
Low CD4 count
The hypothesis that the CMV effect might be mediated through loss of CD4 cells
was investigated. The results presented here suggest that CMV status has a
significant effect on the rate of CD4 decline, as shown by a faster progression to
a CD4 count of 0-05 x 10
9/l in CMV seropositive individuals than in seronegative.
It has previously been shown that there is an effect of age on progression to AIDS
which is not completely explained by more rapidly declining CD4 counts [12].
Certainly, the effects of CMV, age and CD4 count do not act totally independently
of each other. However, results from Table 2 suggest that whilst CMV positives do
indeed progress to a CD4 count of 0-05 x 10
9/l more rapidly than CMV negatives,
largely independently of their age at seroconversion, this rapid drop in CD4 cells
does not fully explain the CMV effect on progression to AIDS. Further functional
studies of activated CD8+ T lymphocytes are required to answer these questions.
In summary, our results show a continued association between CMV and
progression of HIV disease which cannot entirely be explained by age. These
results have implications for both our understanding of the pathogenesis of HIV
and for therapy, which are being actively pursued in clinical trials of anti-herpes
drugs.
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